title: Immunological reconstitution after autologous stem cell transplantation in patients with refractory systemic autoimmune diseases.
abstract: OBJECTIVE
  High-dose chemotherapy followed by autologous haematopoietic stem cell transplantation (AHSCT) can be a salvage therapy for patients with severe, refractory systemic autoimmune diseases. The function of the newly rebuilt immune system is important, but little is known about immune reconstitution after AHSCT in autoimmune disorders. Our aim was to investigate the repopulation of different lymphocyte subsets in patients with systemic autoimmune diseases after AHSCT.
  
  
  METHODS
  Twelve patients with severe refractory, autoimmune diseases were enrolled in the study: four with rheumatoid arthritis (RA), four with systemic sclerosis (SSc), three with systemic lupus erythematosus (SLE), and one with autoimmune overlap syndrome (myositis and RA). After stem-cell mobilization, CD34+ apheresis was carried out, followed by conditioning and AHSCT. After transplantation, peripheral lymphocyte subsets were regularly assessed by flow cytometry.
  
  
  RESULTS
  The follow-up time was 24 months. The overall transplantation-related mortality (TRM) was 16.7% and the transplant-related toxicity was 33% 2 years after AHSCT. Regarding the immune reconstitution, CD56+ natural killer (NK) cells appeared in the earliest phase after transplantation, followed by CD8+ T cells. B cells and CD4+ T cells became normal within 150 days. The ratio of naive cells was low 30 days after AHSCT; however, naive B cells regenerated within 2 months whereas the repopulation of naive T cells took longer. After a short increase, the ratio of memory cells decreased 2 months after transplantation. Regulatory T (Treg) cells did not change significantly in the peritransplant period. Altogether approximately 5-6 months were required for the reconstitution of the peripheral immune network.
  
  
  CONCLUSIONS
  AHSCT can be a salvage therapeutic modality in autoimmune patients who are refractory to other conventional therapies.
authors.affiliation: Institute of Immunology, Rikshospitalet, University of Oslo, Norway. szodoray@gmail.com
authors.forename: P
authors.initials: P
authors.lastname: Szodoray
authors.forename: L
authors.initials: L
authors.lastname: Varoczy
authors.forename: G
authors.initials: G
authors.lastname: Papp
authors.forename: S
authors.initials: S
authors.lastname: Barath
authors.forename: B
authors.initials: B
authors.lastname: Nakken
authors.forename: G
authors.initials: G
authors.lastname: Szegedi
authors.forename: M
authors.initials: M
authors.lastname: Zeher
mesh_terms: D000328:Adult; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000473:pathology / Q000601:surgery*; D005434:Flow Cytometry; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D007107:Immune System / Q000276:immunology* / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000473:pathology / Q000601:surgery*; D018655:Lymphocyte Count; D016131:Lymphocyte Subsets / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009220:Myositis / Q000276:immunology / Q000473:pathology / Q000601:surgery; D016879:Salvage Therapy; D012595:Scleroderma, Systemic / Q000276:immunology / Q000473:pathology / Q000601:surgery*; D033581:Stem Cell Transplantation / Q000401:mortality; D015996:Survival Rate; D016896:Treatment Outcome